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Endothelin-1 (ET-1) is involved in the pathogenesis of cardiac and renal diseases, and in the progression 
of tumour growth in cancer, but current diagnosis and treatment remain inadequate. Peptides derived 
from the 212 amino acid precursor preproendothelin-1 (ppET-1) may have utility as biomarkers, or 
cause biological effects that are unaffected by endothelin receptor antagonists. Here, we used specific 
immunoassays and LC-MS/MS to identify NT-proET-1 (ppET-1[18–50]), Endothelin-Like Domain Peptide 
(ELDP, ppET-1[93–166]) and CT-proET-1 (ppET-1[169–212]) in conditioned media from cultured endothelial 
cells. Synthesis of these peptides correlated with ET-1, and plasma ELDP and CT-proET-1 were elevated 
in patients with chronic heart failure. Clearance rates of NT-proET-1, ELDP and CT-proET-1 were 
determined after i.v. injection in anaesthetised rats. CT-proET-1 had the slowest systemic clearance, 
hence providing a biological basis for it being a better biomarker of ET-1 synthesis. ELDP contains 
the evolutionary conserved endothelin-like domain sequence, which potentially confers biological 
activity. On isolated arteries ELDP lacked direct vasoconstrictor effects. However, it enhanced ET-1 
vasoconstriction and prolonged the increase in blood pressure in anaesthetised rats. ELDP may 
therefore contribute to disease pathogenesis by augmenting ET-1 responses.
The 21-amino acid vasoconstrictor peptide endothelin-1 (ET-1) was first described almost 30 years ago1. 
Subsequent research has strongly linked increased expression of ET-1 to pathological processes underlying car-
diovascular, renal and lung diseases2–6, where it not only acts as a vasoconstrictor but also causes inflamma-
tion, vascular remodelling and fibrosis7–13. ET-1 peptides also play a role in cancer cell proliferation and tumour 
growth14. Current use of endothelin receptor antagonists (ERA) is mainly restricted to treatment of pulmonary 
hypertension5, 6. Other disease areas, particularly those involving fibrosis or tumour growth, are largely resistant 
to ERA treatment14. However, observations that over expression of the EDN1 gene leads to a lethal heart failure 
that is not prevented by ERA indicate that there are undiscovered aspects of endothelin biology that require fur-
ther investigation7.
There are three endothelin isoforms – ET-1, ET-2 and ET-3 – generated from three separate genes15. ET-1 is 
the main isoform expressed in the cardiovascular system. Human ET-1 is derived from a 212 amino acid precur-
sor – preproET-1 (ppET-1)16, 17. All three isoforms are 21 amino acids long and contain four Cys residues that 
form two intra-chain disulphide bridges at Cys1–Cys15 and Cys3–Cys111, 15. This unusual structure is an evolution-
ary conserved characteristic of this family of peptides18, 19.
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Processing of ppET-1 occurs intracellularly20. This involves removal of the N-terminal signal sequence, pre-
dicted to be preproET-1[1–17]16, 17, by a signal peptidase in the endoplasmic reticulum as the nascent ET-1 precur-
sor enters the secretory pathway21. This generates proET-1 (ppET-1[18–212]), which enters the constitutive secretory 
pathway via the trans Golgi network and is then transported to the cell surface in constitutive secretory vesicles20. 
Processing of proET-1 to ET-1 occurs in transit to the cell surface, following a pattern consistent with other bio-
logically active peptide prohormones. This involves specific proteolytic cleavage on the C-terminal side of double 
basic amino acid residues (most commonly at Lys-Arg and Arg-Arg) by prohormone/proprotein convertases, and 
is followed by removal of C-terminal basic residues by carboxypeptidase H22. Cleavage at double basics residues 
generates the inactive intermediate bigET-1, which is converted intracellularly by endothelin-converting enzyme 
to ET-120. Processing of proET-1 at double basic residues yields additional peptide fragments that are co-secreted 
with the biologically active ET-1 from endothelial cells and other cells synthesising ET-123. These peptide frag-
ments are generally considered to be biologically inert, but can act as biomarkers of ET-1 release24, 25.
Here we describe the detailed characterisation of the peptide products of intracellular processing of proET-1 – 
namely, NT-proET-1 (ppET-1[18–50]), Endothelin-Like Domain Peptide (ELDP, ppET-1[93–166]) and CT-proET-1 
(ppET-1[169–212]) (Fig. 1). To assess their relative utility as biomarkers of disease, plasma concentrations in patients 
with chronic heart failure were compared to subjects free of symptoms of heart disease. To determine whether 
metabolism in the circulation influenced plasma levels of these peptide fragments relative clearance rates were 
measured in anaesthetised rats after i.v. injection. Finally, given the structural homology to ET-1, we examined 
whether ELDP displayed vasoconstrictor activity or modified the effects of ET-1.
Results
Initial characterisation of secreted proET-1 derived peptides. To identify the peptide products gen-
erated by intracellular processing of proET-1, two ET-1 producing cell lines were used: EA.hy 926 and A54926–28. 
EA.hy 926 is a human hybridoma cell line with characteristics of endothelial cells26, which was created by fusing 
human umbilical vein endothelial cells with A549 cells (a human lung carcinoma cell line with epithelial cell 
characteristics27). Initial characterisation focused on identifying the peptides produced on cleavage of the double 
basic residues flanking big ET-1. To achieve this ammonium sulphate peptide precipitates were prepared from 
conditioned media collected after 48 h incubation with EA.hy 926 and A549 cell lines, and subjected to size exclu-
sion chromatography on Sephadex G50 (Fig. 2). Immunoassay of fractions for ppET-1[42–50] identified a single 
peptide peak from both cell lines. The estimated molecular weight was ≈6 kD based on elution of reference pep-
tides (Fig. 2A and B), compared to its theoretical mass of 3430. This anomaly may be due to NT-proET-1 having 
a larger hydrodynamic radius than the reference peptides, which all contained disulphide bonds and likely have 
more compact structures. Nevertheless, this indicated that NT-proET-1 is synthesised as the full-length peptide 
resulting from removal of the signal peptide and processing at Lys51-Arg52 (Fig. 1).
Immunoassay for ppET-1[93–102] also identified a signal peak (Fig. 2A and B) from both cell types. This cor-
responded to a molecular weight of ≈8–9 kD, representing a long internal sequence of proET-1. Based on the 
size of the peptide it was hypothesised that processing at double basic residues occurred at Arg164-Lys165 or 
Arg167-Arg168 (Fig. 1). If processing occurred at the earlier of these paired residues the resulting C-terminal Gly163 
would likely be converted to Arg162-amide by peptidylglycine alpha-amidating monooxygenase29. Therefore, to 
identify the C-terminal of this peptide, antisera were raised against ppET-1[155–162-amide] and ppET-1[155–166]. Native 
peptide in conditioned media samples was only recognised by ppET-1[155–166] antiserum, which indicated that 
this large peptide from the mid-portion of proET-1 was ppET-1[93–166] (theoretical mass 8637), which we called 
Endothelin-Like Domain Peptide (ELDP) because of the evolutionary conserved endothelin-like domain18, 19.
Based on this initial characterisation of proET-1 derived peptides in these conditioned media samples we 
hypothesised that the following peptides were generated by proET-1 processing – NT-proET-1 (ppET-1[18–50]), 
ELDP (ppET-1[93–166]) and CT-proET-1 (ppET-1[169–212]) (Fig. 1). To confirm this we developed double-recognition 
site sandwich immunoassays using peptide antigens that represented the N- and C-terminal sequences for each 
of these peptides (Table 1).
Figure 1. Amino acid sequence of preproendothelin-1 indicating the peptide products generated by processing 
at double basic residues.
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Purification and LC-MS/MS characterisation of proET-1 peptides. ELDP and CT-proET-1 were 
isolated from conditioned media collected from EA.hy 926 cells by cation-exchange (Fractogel CEx) chroma-
tography after passing the acidified media through a strong anion exchange gel (Q-Sepharose FF). The elution 
characteristics of these peptides were typical of their high isoelectric points (ELDP pI 9.4; CT-proET-1 pI 10.5) 
Figure 2. Size exclusion chromatography of peptide precipitates from (A) EA.hy 926 and (B) A549 cell lines, 
(C) cation exchange chromatography of conditioned media from EA.hy 926, and HPLC characterisation 
of pro-ET-1 peptides from EA.hy 926 cells – (D) NT-proET-1, (E) ELDP and (F) CT-proET-1. (A) and (B) 
proendothelin-1 peptides from EA.hy 926 and A549 cell lines were subjected to size exclusion chromatography 
(column 1.6 × 100 cm, Sephadex G50 superfine) equilibrated at 4 °C with 0.1 M NaCl containing 0.01 M HCl. 
Fractions were subjected to immunoassay for ppET-1[42–50] (open circles) and ppET-1[93–102] (closed circles). 
Elution positions of adrenomedullin (ADM, Mr 6029), big ET-1 (bET-1, Mr 4283) and ET-1 (Mr 2492) are 
indicated. (C) Cation-exchange chromatography of 300 ml of acidified (1.25% acetic acid) conditioned medium 
from EA.hy 926 cells loaded onto ten Fractogel CEx columns (bed volume 2.8 ml each) after Q-Sepharose FF 
pre-treatment. After rinsing with 10 mM acetic acid (10 ml/column) to remove unadsorbed material (UA), 
columns were eluted sequentially (3 ml each) with: (1) 0.125 M NaCl, (2) 0.25 M NaCl, (3) 0.25 M NaCl + 0.1 
M G-HCl, (4) 0.5 M NaCl + 0.1 M G-HCl, (5) 1 M NaCl + 0.1 M G-HCl, (6–10) 1 M NaCl + 0.5 M G-HCl. 
ELDP (red columns) and CT-proET-1 (blue columns) were measured using immunoassays. (D), (E) and (F) 
peak fractions of NT-proET-1, ELDP and CT-proET-1 from semi-preparative RP-HPLC were pooled and 
subjected to separate RP-HPLC purification (ACE-5 C4 300 Å, 5 µm, 4.6 × 250 mm) with gradient elution (1 ml/
min) 0.1% TFA – 10% solvent B (80% CH3CN with 0.1% TFA) over 2 min, followed by 10–30% B over 50 min. 
Fractions (1 min) were subjected to specific sandwich immunoassay to identify peak fractions for LC-MS/MS 
characterisation. Arrows mark the elution positions of synthetic NT-proET-1, ELDP and CT-proET-1; which 
eluted in fractions 46, 45 and 28, respectively.
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(Fig. 2C). NT-proET-1 (pI 6.3) immunoreactivity was mainly present in the unadsorbed pooled sample that 
had passed through both Q-Sepharose FF and Fractogel CEx. Subsequent isolation of NT-proET-1 immunore-
activity, initially by extraction from this unadsorbed material on C2-silica cartridges, resulted in a single peak 
on reverse-phase HPLC, which eluted several fractions earlier than synthetic standard (Fig. 2D). Trp oxidation 
or deamidation of Asn during the isolation process likely accounts for the reduced hydrophobicity of native 
NT-proET-1. Based on antibody crossreactivity, and characteristics on ion-exchange chromatography and 
RP-HPLC, it seems likely that purified NT-proET-1 corresponded to the predicted amino acid sequence ppET-
1[18–50]16, 17. However, there was insufficient purified peptide for confirmation of this by UPLC–MS/MS, despite 
pre-optimization of the elution conditions using synthetic NT-proET-1.
Purification of ELDP and CT-proET-1 by HPLC revealed elution characteristics of the purified native peptides 
very similar to synthetic peptide standards (Fig. 2E and F). The slight heterogeneity of both purified peptides, 
based on elution profile, was likely due to oxidation (His, Met, or Trp), and side chain hydrolysis of Asn and 
Gln during incubation in conditioning media prior to collection or as a consequence of the purification con-
ditions (these modifications were observed on LC-MS/MS, Supplementary Tables S1 and S2). To enable detec-
tion of peptides with intact disulphide bridges trypsin digestion was performed without reduction or alkylation. 
Partial amino acid sequence was obtained for these purified peptides by LC-MS/MS. For ELDP, the peptides 
identified covered the ppET-1[128–144] and ppET-1[155–162] sequences (Supplementary Table S1, and Supplementary 
Figure S1), but no peptides containing disulphide bridges were detected. Analysis of synthetic ELDP following 
the same protocol also failed to identify the disulphide bridge structures, indicating the technical limitations of 
this approach. The endothelin-like domain sequence is rich in Lys, with four potential cleavage sites. Manual 
inspection of MS/MS data for all potential products of trypsin hydrolysis failed to identify any relevant peptides, 
suggesting that these relatively hydrophilic peptides were lost during sample preparation.
For purified CT-proET-1, amino acid sequences were identified that covered the majority of the proposed 
sequence (ppET-1[169–212]). Importantly, this included identification of the N-terminal sequence of CT-proET-1, 
ppET-1[169–183] SSEEHLRQTRSETMR (Supplementary Table S2, and Supplementary Figure S2). When consid-
ered in conjunction with antibody recognition of ppET-1[155–166], and LC-MS/MS identification of CIYQQLVR 
(ppET-1[155–162]) from the C-terminal sequence of ELDP, it can be concluded that ELDP is not processed to 
amidated ppET-1[93–162-amide] (Supplementary Table S1, and Supplementary Figure S1). Hence confirming that 
Arg167-Arg168 is the ppET-1 processing site (155-CIYQQLVRGRKIRRSSEEHLRQTRSETMR-183). Antibody rec-
ognition by sandwich ELISA and elution characteristics of synthetic and purified native peptides, also strongly 
support the identities of ELDP and CT-proET-1 as ppET-1[93–166] and ppET-1[169–212].
Evaluation of proET-1 peptides as biomarkers of ET-1 synthesis. To confirm that proET-1 peptides 
are a reproducible index of ET-1 synthesis we compared the level of peptide production in cultured human aor-
tic endothelial cells under conditions known to increase or decrease ET-1 expression. These experiments also 
confirmed that early passage human endothelial cells from primary cultures produce the same peptides with the 
stoichiometric relationship expected for proET-1 processing. Treatment with phosphoramidon (PHA, 1 mM), 
an endothelin-converting enzyme inhibitor which blocks processing of big ET-1 to ET-1 without changing the 
overall level of proET-1 synthesis30, suppressed ET-1 synthesis with a consequent 14.9 ± 2.8 fold increase in big 
ET-1 compared to basal (Fig. 3). PHA had no effect on proET-1 peptide production showing that inhibition of 
endothelin-converting enzyme does not affect processing at double basic residues.
Apple procyanidin pentamer (AP 2.5 or 5 μg/ml) and a procyanidin-rich grape seed extract, which cause con-
centration dependent suppression of EDN1 gene expression31, 32, reduced the synthesis of all peptides. Stimulation 
with TNFα (10 ng/ml) increases EDN1 mRNA levels33. Consistent with this, levels of NT-proET-1 and 
CT-proET-1 in conditioned media samples significantly increased. ET-1 and ELDP did not change, which may 
indicate increased clearance of the secreted peptides due to TNF-induced peptidase activity or receptor-mediated 
clearance. This may be further compounded by reduced processing efficiency of proET-1, as big ET-1 concen-
trations increased with TNFα, so that increased mRNA levels were not reflected by increased secretion of ET-1 
and ELDP. In comparison, TGFß significantly increased secretion of ET-1, big ET-1 and all the proET-1 peptides 
(Fig. 3). After excluding measurements made in the presence of PHA, ET-1 output was closely correlated with 
synthesis of all proET-1 peptides (Fig. 3), indicating their potential utility as circulating biomarkers that reflect 
ET-1 synthesis.
To compare the relative potential of the three proET-1 peptides as biomarkers of cardiovascular disease, 
plasma levels were measured in patients with chronic heart failure due to ischemic heart disease and compared to 
control subjects with pre-hypertension/mild hypertension who were free of symptoms of heart disease (Table 2). 
ProET-1 peptide sequences Capture Ab/Protein Conjugate Species Detection Ab/Protein Conjugate Species
NT-proET-1 (ppET-1[18–50]): APETAVLGAELSAV 
GENGGEKPTPSPPWRLRRS ppET-1[18–30]/Maleimide Rabbit ppET-1[42–50]/Glutaraldehyde Rabbit
ELDP (ppET-1[93–166]): ALENLLPTKATDRENRCQCASQKDKKCWNFCQ 
AGKELRAEDIMEKDWNNHKKGKDCSKLGKKCIYQQLVRGRKI ppET-1[93–109]/Maleimide Sheep ppET-1[155–166]/Maleimide Sheep
CT-proET-1 (ppET-1[169–212]): SSEEHLRQTRSETMRNSV 
KSSFHDPKLKGKPSRERYVTHNRAHW ppET-1[169–186]/Maleimide Sheep ppET-1[204–212]/Glutaraldehyde Rabbit
Table 1. Antibodies used for proendothelin-1 sandwich immunoassays. Amino acid numbering is based on 
the 212 amino acid sequence for preproendothelin-1 (ppET-1). Underlined sequences in bold type indicate 
peptides used as antigens to raise specific antisera for the development of capture and detection antibodies.
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Figure 3. Correlation between secretion of ET-1 and proET-1 peptides from human aortic endothelial cells. 
Confluent cultures were incubated for 6 h in basal medium alone, or with 1 mM phosphoramidon (PHA), 2.5 
or 5 µg/ml apple procyanidin pentamer (AP-2.5, AP-5), 5 µg/ml grape seed extract (GSE), 10 ng/ml TNFα or 
1 ng/ml TGFß. All peptides were measured using specific sandwich ELISAs, and converted to % basal release 
(A,B,C,E and G). Results are mean ± SD from 4 experiments. Significant differences were determined by 
ANOVA with Bonferroni correction for multiple comparisons (*P = < 0.05; ***P = < 0.001). (D,F) and (H) 
show correlations between secretion of ET-1 and the respective proET-1 peptides under the different incubation 
conditions (excluding data obtained with phosporamidon).
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Assay of NT-proET-1 failed to detect this peptide in plasma samples. Both ELDP and CT-proET-1 were sig-
nificantly higher in samples from patients with chronic heart failure versus those with pre-hypertension/mild 
hypertension (p < 0.001) (Fig. 4A). Consistent with the stoichiometric co-synthesis of these peptides with ET-1, 
concentrations of ELDP correlated with CT-proET-1 (p < 0.001, r = 0.66) (Fig. 4B), which adds further support 
for these peptides being an index of ET-1 expression. CT-proET-1 concentrations were ≈80% greater than the 
corresponding ELDP values (p < 0.001; mean ± SD: ELDP 7.1 ± 1.3, CT-proET-1 13.1 ± 4.5 fmol/ml), indicating 
that clearance or metabolism of these peptides may differ.
It is already recognised that measurements of CT-proET-1 predict outcome in patients with chronic heart 
failure34, 35. To confirm that CT-proET-1 was a better a biomarker than ELDP for evaluating the severity of chronic 
heart failure, values for the two assays were compared using ROC analyses (Fig. 4C). Table 3 shows the area under 
the curves (AUC) for the two assays, and the sensitivity and specificity at various cutoffs – where sensitivity is 
the proportion of patients with chronic heart failure with a value greater than the cut-off, and specificity is the 
proportion of controls below this level. Both ELDP and CT-proET-1 showed good discrimination for patients 
with heart failure from individuals without heart disease (Table 3). The AUC for CT-proET-1 was significantly 
greater than ELPD (0.934 compared to 0.805, P = 0.019), indicating that it was a more sensitive biomarker and 
most likely to have diagnostic utility. For CT-proET-1 75.0% of patients with heart failure had values >13.89 fmol/
ml and 95.8% of control subjects were below this level.
Consistent with previous biomarker studies in chronic heart failure where CT-proET-1 correlated with B-type 
natriuretic peptide (BNP)34, and log CT-proET-1 correlated with log N-terminal-proBNP (NT-proBNP)35, here 
CT-proET-1 correlated with NT-proBNP (Fig. 4D). A number of biomarkers of inflammation are elevated in 
chronic heart failure including IL-8, which is an independent predictor of outcome36. In this group of patients 
with stable chronic heart failure IL-8 correlated with CT-proET-1 (Fig. 4E) even though IL-8 did not correlate 
with NT-proBNP (Fig. 4F). This suggests that CT-proET-1 reflects both the level of inflammation and the degree 
of myocardial dysfunction in chronic heart failure. In agreement with ELDP being a less sensitive biomarker than 
CT-proET-1, its correlation with NT-proBNP or IL-8 did not reach statistical significance. In comparisons with 
other inflammation biomarkers, neither CT-proET-1 nor ELDP correlated with CRP, IL-6, MCP-1 or TNF (for 
all r ≤ 0.19 and p ≥ 0.4).
Comparison of proET-1 peptide clearance rates. To examine whether circulating half-lives influ-
enced plasma levels of proET-1 peptides clearance rates were investigated in anaesthetised rats. Bolus adminis-
tration (1 nmol/kg i.v. of each peptide as a combined solution) showed markedly different elimination rates for 
NT-proET-1, ELDP and CT-proET-1 (p < 0.001; Fig. 5). Based on a circulating blood volume of 7.2 ± 0.3 ml per 
100 g body weight37, a mean weight of 345 ± 6 g and hematocrit of 40–60%, the hypothetical maximum plasma 
concentrations were 23–35 pmol/ml. However, the levels of NT-proET-1, ELDP and CT-proET-1 30 s after injec-
tion were 0.29 ± 0.02, 3.65 ± 0.23, and 11.74 ± 0.64 pmol/ml, respectively. Relative to estimates for dilution in 
circulating blood, these values represent ≈1%, 10–16%, and 34–51% of administered peptide for NT-proET-1, 
ELDP and CT-proET-1. Moreover, NT-proET-1 was almost completely cleared from the circulation in <5 min 
(estimated initial t½ < 20 s). Clearance rates for ELDP and CT-proET-1 showed two phases with estimated t½ 
Chronic Heart Failure Hypertension
n 24 24
Age (years) 70 ± 2.0 55.4 ± 1.5
Male gender 20 (80%) 24 (100%)
Weight (kg) 85.7 ± 4.3 80.4 ± 3.0
Body Mass Index (kg/m2) 29.6 ± 1.2 26.7 ± 0.5
Systolic Blood Pressure (mmHg) 126.3 ± 3.6 144.8 ± 2.1
Diastolic Blood Pressure (mmHg) 71.0 ± 2.0 87.1 ± 1.3
Heart rate (bpm) 64.0 ± 1.4 69.3 ± 2.0
NYHA chronic HF Class II/III 20 (80%)/4 (20%) —
LVEF (%) 31.2 ± 2.0 —
NT-proBNP (pg/ml) 1970 ± 288 —
CRP (mg/L) 4.05 ± 3.60 —
IL-6 (pg/ml) 2.90 ± 1.05 —
IL-8 (pg/ml) 9.58 ± 3.46 —
MCP-1 (pg/ml) 56.0 ± 22.7 —
TNFα (pg/ml) 3.12 ± 1.31 —
Total cholesterol (mmol/L) 4.25 ± 0.24 5.73 ± 0.20
LDL-cholesterol (mmol/L) 2.14 ± 0.25 3.53 ± 0.15
HDL-cholesterol (mmol/L) 1.29 ± 0.07 1.58 ± 0.06
Triglycerides (mmol/L) 1.75 ± 0.18 1.39 ± 0.11
Table 2. Patient information.
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values of 0.5 and 0.7 min for phase 1, and 5.7 and 7.3 min for phase 2, with CT-proET-1 having significantly slower 
clearance than ELDP (P < 0.001) (Fig. 5).
Cardiovascular effects of ELDP. The endothelin-like domain sequence is highly conserved with the first 
four Cys residues having identical spacing to ET-1 (Fig. 6)18, 19. There is also considerable sequence homology 
adjacent to the endothelin-like domain, which has been retained throughout mammalian evolution, such that 
human ppET-1[107–131] has 92% sequence identity with mouse ELDP and 88% with platypus over this sequence. 
Although this is suggestive of biological activity, previous attempts to demonstrate this for ppET-1[110–130] failed 
to show any cardiovascular effects38. However, choice of test conditions and peptide structure may be critical for 
Figure 4. Comparison of plasma levels of ELDP and CT-proET-1 in hypertension and chronic heart failure. 
(A) Concentrations of ELDP and CT-proET-1 (mean ± SD) in each group (n = 24 per group) were compared 
by Student’s t-test, ***p < 0.001. (B) Correlation between individual plasma levels of ELDP and CT-proET-1 
(open circles patients with hypertension, closed circles patients with chronic heart failure). (C) Comparison of 
ROC analyses for ELDP and CT-proET-1 detection of chronic heart failure. (D) and (E) Correlation between 
individual plasma levels of ELDP (red circles) and CT-proET-1 (blue circles) with NT-proBNP and IL-8 in 
patients with chronic heart failure. (F) Comparison of plasma levels of NT-proBNP and IL-8 in chronic heart 
failure.
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revealing the actions of ELDP. The C-terminal sequence of ELDP may be required for receptor binding, and hence 
for biological activity, as there are two additional Cys residues (ppET-1 Cys148 and Cys155) (Fig. 6), which have 
retained a consistent spacing from platypus to human, with several adjacent residues in the C-terminal sequence 
of ELDP (ppET-1[143–166]) being fully conserved (Lys143, Lys144, Gly152, Lys154, Gln159, Leu160, Val161 and Lys165) and 
others being mainly conservative substitutions.
Here, ELDP[162-amide] alone (up to 10 nM) had no significant vasoconstrictor effect on rat mesenteric resist-
ance arteries. However, after pre-treatment with ET-1 (1–3 nM) to induce a degree of vascular tone (≈10% 
vasoconstriction), ELDP[162-amide] produced a concentration-dependent vasoconstriction (Fig. 7A). In addition, 
pre-incubation of resistance arteries with 10 nM ELDP[162-amide] increased the response of 1 nM ET-1 by ≈5 fold 
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Table 3. ROC analyses for sensitivity and specificity of plasma assays of ELDP and CT-proET-1 for detection of 
chronic heart failure.
Figure 5. Comparison of clearance rates of NT-proET-1, ELDP and CT-proET-1 in anaesthetised rats. A bolus 
dose containing 1 nmol/kg of each proET-1 peptide as a combined solution prepared in 0.9% saline/0.1% BSA 
was administered i.v. and heparinised arterial blood samples (0.5 ml) were collected at 0.5, 1, 2, 5, 10, 20 and 
40 min after administration of proET-1 peptides. NT-proET-1 (mauve circles), ELDP (red circles) and CT-
proET-1 (blue circles) were measured by magnetic bead-based multiplex assays using Luminex methodology 
(values are mean ± SD, except where SD is less than the symbol size). Clearance rates for the three peptides were 
significantly different from each other (2-way ANOVA, P = < 0.001).
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effect on blood pressure in anaesthetised rats, but it significantly increased the duration of the pressor response 
to ET-1 (0.3 nmol/kg) administered 15 min after ELDP (P < 0.02, Fig. 7C) without changing the magnitude of the 
initial pressor response.
Discussion
Ever since C-peptide of proinsulin was recognised as a better index of insulin secretion than measuring cir-
culating insulin39, research on biomarkers has frequently investigated the utility of other fragments of prohor-
mone precursors. This strategy has been applied successfully to BNP40, adrenomedullin34, and copeptin (the 
Figure 6. Inter species comparison of the conserved EDN1 gene derived endothelin-like domain peptide 
(ELDP) with ET-1. The single line indicates the endothelin-like domain, with alignment of human ELDP and 
ET-1. Shaded residues indicate homology with human ELDP, and asterisks indicate conserved Cys residues. 
Peptide sequences are from the UniProt KnowledgeBase: human (Homo sapiens, P05305), chimpanzee (Pan 
troglodytes, H2QSB1), mouse (Mus musculus, P22387), opossum (Monodelphis domestica, F6YR31), duckbill 
platypus (Ornithorhynchus anatinus, F6WZM8), chicken (Gallus gallus, F1NWA9), green anole lizard (Anolis 
carolinensis, H9GDX1), and zebrafish (Danio rerio, A5WW41).
Figure 7. Cardiovascular effects of ELDP. (A) and (B) isolated rat mesenteric resistance arteries; (A) effect of 
ELDP[162-amide] alone (white circles, n = 12) or after pre-treatment with ET-1 (1–3 × 10−9 M) to induce ≈10% 
vasoconstriction relative to the maximal response to phenylephrine (10 µM) (red circles, n = 7) (**P < 0.01, 
***P < 0.001, compared to the same concentration without ET-1; 1 × 10−8 M ELDP[162-amide] with ET-1 caused 
a significantly greater vasoconstriction than all other concentrations of ELDP[162-amide] with ET-1, P < 0.001; 
2-way ANOVA with Bonferroni correction). (B) vasoconstrictor response to ET-1 (1 × 10−9 M) alone (n = 8) or 
after pre-incubation with ELDP[162-amide] (10 × 10−9 M, n = 10); P < 0.002; Student’s t-test. (C) Change in mean 
arterial blood pressure in anaesthetised rats following ET-1 (0.3 nmol/kg, i.v.) alone (white circles, n = 6) or 
15 min after ELDP (3 nmol/kg i.v.) (red circles, n = 6). Following ELDP the response to ET-1 was significantly 
greater; P < 0.02, by 2-way ANOVA. Results are mean ± s.e.m.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 4956  | DOI:10.1038/s41598-017-05365-2
glycosylated C-terminal peptide of provasopressin)41. Previous work has demonstrated the utility of CT-proET-1 
measurements34, 35, but the precise processing pattern of proendothelin-1 had not been described. Our investiga-
tions identified three products of proET-1 synthesis that are co-secreted with ET-1. This has enabled an assess-
ment of these pro-ET-1 peptides as biomarkers in patient samples, as well as investigations of circulating half-lives 
of these proET-1 peptides in anaesthetised rats to determine whether metabolism has an impact on their utility 
as biomarkers.
After intravenous injection NT-proET-1 was rapidly eliminated from the circulation (t½ < 20 s). Such rapid 
clearance indicates uptake or metabolism. ET-1 also has a short t½ (30–60 s)42, 43, which is due primarily to clear-
ance by endothelial ETB receptors in the pulmonary vasculature44, 45, and to a lesser extent degradation by neu-
tral endopeptidase 24.11, particularly in post capillary veins46, 47. In the absence of receptor-mediated clearance, 
the high disappearance rate of NT-proET-1 is likely due to peptidase activity in the circulation, particularly in 
the pulmonary circulation. Bradykinin (RPPGFSPFR) is the archetypal peptide cleared in transit through the 
lung (t½ < 20 s), primarily by angiotensin converting enzyme (ACE)48, 49. The kinetics of NT-proET-1 clearance 
are consistent with first pass metabolism in the pulmonary vasculature, where ACE may well be responsible as 
it has high affinity for proline-rich sequences49–51, which by analogy may result in the NT-proET-1 sequence 
KPTPSPPWR (ppET-1[38–46]) being a susceptible substrate.
In comparison, ELDP and CT-proET-1 had much longer half-lives. Disappearance of stable peptides from 
the circulation reflects initial dilution in plasma and diffusion into interstitial fluid (phase 1)52, 53. This larger 
volume of distribution, than simple dilution in circulating blood, can account for the lower levels of ELDP and 
CT-proET-1 at 30 sec than theoretical estimates. Once these peptides have reached distribution equilibrium this 
is followed by tissue receptor binding, local tissue metabolism or cellular uptake (phase 2), with this second phase 
being characterised by slower plasma disappearance depending on the tissue clearance mechanisms52, 53. The 
more rapid clearance of ELDP relative to CT-proET-1 may indicate an additional mechanism affecting ELDP 
such as receptor binding.
Increased levels of ELDP and CT-proET-1 in chronic heart failure may be related to the severity of endothe-
lial dysfunction or to chronic cardiomyopathic changes54. The longer circulating t½ of CT-proET-1, compared 
to ELDP, is likely an important factor influencing its higher relative plasma levels. Previous studies describing 
CT-proET-1 as a biomarker of ET-1 synthesis have been based on an assay for ppET-1[168–212], (i.e. a peptide that 
includes an additional N-terminal Arg)25. Nevertheless, our results are consistent with previous studies showing 
elevated levels of CT-proET-1 in chronic heart failure34, 35, as well as during acute decompensated heart failure55, 56. 
CT-proET-1 is also elevated in acute myocardial infarction, where it was an independent predictor of death and 
heart failure57. Our finding that CT-proET-1 correlates with NT-proBNP and IL-8 suggests that measuring these 
three biomarkers in combination may be a powerful predictor of outcome in chronic heart failure, or a better 
index for assessing the effectiveness of new treatments.
The ROC analyses support the superiority of CT-proET-1 over ELDP as a biomarker of chronic heart fail-
ure. Similarly, these assays methodologies showed CT-proET-1 levels were a better index of renal dysfunction 
than ELDP in patients with chronic kidney disease58. Whether reduced renal clearance in heart failure or kidney 
disease affects plasma levels of these peptides is not known. Measurements of CT-proET-1 (ppET-1[168–212]) in 
healthy volunteers showed no significant difference between male (n = 300) and females (n = 218)59. However, 
weak correlations with age and renal function were reported59. One of the important limitations of studying 
metabolism of human peptides in animal models is knowing whether the same pattern of peptidase degrada-
tion occurs in the human circulation. Therefore, to extend findings to date, and to provide further validation of 
CT-proET-1 as a clinical biomarker, infusion studies should be undertaken to define the effect on plasma levels 
of its clearance rate and metabolism in patients with chronic heart failure, chronic renal failure, and age-matched 
control subjects. Assays that also detect metabolites of CT-proET-1 may further increase specificity and sen-
sitivity as a diagnostic tool. However, because chronic disease states are frequently associated with increased 
oxidant stress, an important consideration in biomarker assay development is ensuring amino acid residues that 
are prone to oxidation are avoided in antigens used for raising antibodies because peptides and metabolites will 
not be detected if the recognised epitope becomes oxidised60. The impact of this has been reported for parathy-
roid hormone60, and we observed His, Met and Trp oxidation in purified peptide fragments we isolated (see 
Supplementary Information). In addition, a full range of disease states needs to be examined to exclude other 
potential causes of increased levels such as cancers.
Much of the evidence implicating ET-1 in cardiovascular disease is based on reported increases in tissue 
expression. However, global overexpression of EDN1 (ET+/+) in mice results in significantly lower blood pressure 
compared to wild-type animals61. This has been attributed, at least in part, to kidney tubular effects of ET-161. 
Another factor contributing to this modest reduction in blood pressure with EDN1 overexpression is likely 
compensatory changes in vascular nitric oxide synthesis, because knockout of endothelial nitric oxide synthase 
(eNOS) in ET+/+ mice results in a greater increase in blood pressure than eNOS knockout alone62. Furthermore, 
endothelial specific over expression of EDN1 causes a sustained increase in blood pressure63. These findings high-
light the important differences in potential outcomes of increased EDN1 expression depending on tissue specific 
localisation and whether mechanisms are triggered that offset ET-1 upregulation. Hence, in patients with a degree 
of endothelial dysfunction, increased EDN1 expression is more likely to cause vasoconstriction and increased 
blood pressure64. Although the increase in blood pressure in mice with endothelial ET+/+ was reversed by 
ETA-antagonist treatment63, this is not always the case as the increased blood pressure and arteriolar remodelling 
when endothelial ET+/+ was combined with salt-loading were only partially prevented by ETA-antagonist admin-
istration65. This suggests other peptides derived from proET-1 contribute to the biological effects of EDN1 expres-
sion through yet to be identified receptor mechanisms. Perhaps of most significance is the ERA-resistant heart 
failure resulting from cardiac over expression of human EDN1 in mice, where combined ETA- and ETB-antagonist 
treatment failed to prevent the lethal effects of this transgenic modification7. Our results indicate a potential 
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role for ELDP in disease processes by increasing the magnitude of ET-1 responses, but further investigation is 
required to determine whether ELDP contributes to ERA-resistant effects of EDN1 overexpression.
An important component of ET-1-induced vasoconstriction is Ca2+ influx through voltage-gated L-type 
Ca2+ channels66, 67. Modulation of ET-1 responses by ELDP therefore likely involves facilitation of Ca2+ influx. 
Responses to norepinephrine and serotonin are also augmented by ET-1, and this has been attributed to increased 
Ca2+ influx68–70. To investigate whether ELDP mediates its effects via a distinct G-protein coupled receptor 
(GPCR), whose ligand pairing had yet to be assigned, ELDP was evaluated against a panel of cell-expressed 
orphan GPCRs using a detection system based on ß-arrestin binding (Supplementary Figure S3). This screen 
failed to identify an ELDP receptor – ligand pair. Negative results could be due to: the relevant GPCR not being 
included in the test panel, inadequate stability of ELDP during incubations, or failure to induce receptor binding 
of ß-arrestin because of G-protein biased receptor signalling71, 72. Alternatively, ELDP responses may be mediated 
through a mechanism distinct from GPCR activation.
Vascular smooth muscle P2X1 receptors represent a good example of non-GPCR modulation of vasocon-
strictor responses73. P2X1 receptor responses are similar to those of ELDP as P2X1 stimulation has little effect 
in the absence of vascular tone, but it potentiates other vasoconstrictors including ET-174, 75. Activation of this 
ligand-gated ion channel by ATP leads to Ca2+ influx and membrane depolarization, which causes further Ca2+ 
entry via voltage-gated Ca2+ channels and lowers the threshold for vasoconstriction73. ELDP-induced vaso-
constriction following partial pre-constriction with ET-1 is consistent with a ligand-gated ion channel reduc-
ing the threshold for vasoconstriction and augmenting ET-1 induced Ca2+ entry73–75. Hence, the receptor target 
for ELDP may be an ion channel with similar properties to the P2X1 receptor. Certainly, the high degree of 
sequence conservation for ELDP during evolution is likely due to the structural constraints of a specific receptor 
target. Ligand-gated ion channels show a high degree of evolutionary conservation76, 77, but the pharmacology, 
including ligands activating some of these family members, has yet to be fully investigated77, and may be rele-
vant receptor targets for ELDP. Modulation of ET-1 responses by ELDP also has implications for treatment of 
non-cardiovascular diseases, such as cancer and fibrosis, where ETA-receptor antagonists are generally ineffective 
despite strong evidence that EDN1 expression is involved in disease progression14. Moreover, ligand-gate ion 
channels have been implicated in cancer cell proliferation78.
In summary, our investigations identified three fragments generated by intracellular processing of proET-1 
– NT-proET-1, ELDP and CT-proET-1. These peptides are co-secreted with ET-1 and closely correlate with 
ET-1 synthesis. Assessment of these peptides as biomarkers confirmed previous investigations demonstrating 
CT-proET-1 has the greatest potential as a diagnostic tool for detecting EDN1-linked pathologies. Furthermore, 
evaluation of the systemic clearance of these proET-1 peptides in anaesthetised rats has provided a physiological 
basis for the higher relative levels of CT-proET-1. Identification of ELDP as the evolutionary conserved proET-1 
fragment containing the endothelin-like domain has enabled an initial examination of its biological activity. This 
indicates the potential for ELDP to have pathophysiological effects, which merit further investigation.
Materials and Methods
Synthetic peptides. Peptide sequences of proET-1 peptides are shown in Fig. 1. NT-proET-1 (ppET-1[18–50]), 
ELDP (ppET-1[93–166]) and CT-proET-1 (ppET-1[169–212]) were chemically synthesised using Boc chemistry on a 
modified ABI 433 synthesiser as described79. ELDP was produced by total chemical synthesis using native chem-
ical ligation to link an N-terminal fragment (residues 1–30; ppET-1[93–122]) with a C-terminal fragment (residues 
31–74; ppET-1[123–166]) containing an N-terminal Cys residue80. Refolding of ELDP and formation of disulphide 
bridges was carried out overnight by stirring a solution of the peptide (0.1 mg/ml) in 0.1 M Tris HCl pH 8.0 with 
2 M guanidinium chloride (G-HCl) and reduced/oxidised glutathione 0.5/0.1 mM. The following day the solution 
was acidified and purified by reverse-phase chromatography. ELDP[162-amide] (ppET-1[93–162-amide]) was synthesised 
following the same approach with a C-terminal fragment of residues 31–70 (ppET-1[123–162] with C-terminal argi-
nine-amide). Purity of all peptides was confirmed by HPLC and mass spectrometry.
ProET-1 antibodies and immunoassays. Underlined sequences in Table 1 indicate peptide antigens 
used to raise specific antisera for sandwich immunoassays following previously described methodologies30. 
Immunogens for ppET-1[93–109] and ppET-1[155–166] were prepared by conjugation via terminal Cys residues to 
maleimide groups on pre-treated carrier proteins30. To enable conjugation of ppET-1[18–30], ppET-1[93–102] and 
ppET-1[169–186] by the maleimide methodology, synthetic peptides for these antigens included a C-terminal 
Cys-NH2 residue. Immunogens for ppET-1[42–50] and ppET-1[204–212] were prepared by glutaraldehyde conjuga-
tion to carrier protein30. For initial characterisation of conditioned media samples, rabbit antisera raised against 
ppET-1[42–50] and ppET-1[93–102] were used to establish radioimmunoassays for these peptide antigens. Subsequent 
investigations used sandwich ELISA methodologies with specific IgG purified from antisera using the respective 
peptide antigens (Table 1) coupled to SulfoLink Coupling Resin (Thermo Scientific/Pierce) or CNBr-Sepharose 
(GE Healthcare)30. Purified IgG for use as detection antibodies were biotinylated with NHS-LC-LC-biotin 
(Thermo Scientific/Pierce), and used for assay measurements with enhanced chemiluminescence30.
A multiplexed immunoassay system was used for simultaneous measurement of NT-proET-1, ELDP and 
CT-proET-1 in small volumes of rat plasma. Capture antibodies were conjugated to magnetic beads (region 
45 – NT-proET-1, region 36 – ELDP, and region 27 – CT-proET-1) following standard protocols (Luminex 
Corporation). For assay capture antibody-coated magnetic beads were diluted as a premixed combination (10 µl/
well) and incubated overnight at 4 °C on an orbital plate mixer with plasma (15 µl) and assay buffer (135 µl). 
For detection, beads were washed using a ring magnet plate washer before adding 25 µl of combined biotiny-
lated detection antibodies and incubating for 2 h at room temperature on an orbital plate mixer. Detection was 
achieved with streptavidin-phycoerythrin (25 µl/well) incubated for 30 min at room temperature before reading 
on a Luminex 200 System.
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Cell Culture. EA.hy 926 and A549 cell lines were grown in Dulbecco’s modified Eagle medium with 10% fetal 
bovine serum at 37 °C in a humidified CO2 incubator (8% CO2, 92% air) as previously described28, 30. Human 
aortic endothelial cells were passaged cells from primary cultures grown in endothelial cell basal medium with 
growth supplement (Cell Applications Inc.), and used when confluent to compare secretion of proET-1 peptides 
with ET-1. Purified apple procyanidin pentamer was from Asahi Breweries (Moriya, Ibaraki 302–0106, Japan), 
grape seed extract was form Polyphenolics (Madera, CA), TNFα and TGFβ were from R&D Systems.
Characterisation and purification of proET-1 peptides. For initial characterisation of proET-1 process-
ing, confluent cultures of EA.hy 926 and A549 cell lines were incubated for 48 h with serum-free DMEM (30 ml/T-
175 cm2 flask) containing peptidase inhibitors (1 mM bacitracin, 10 µM phosphoramidon, 10 µM leupeptin, 10 µM 
chymostatin and 1 µM pepstatin A). Proendothelin-1 peptides were isolated by precipitation with ammonium sul-
phate (90% saturation at 4 °C) and characterised by size exclusion chromatography (Fig. 2A and B).
For purification of proET-1 peptides for LC-MS/MS characterisation, serum free conditioned media was col-
lected after 48 h incubation with confluent cultures of EA.hy 926 cells in T175 cm2 flasks (25 ml media/flask) 
was acidified with 1.25% CH3COOH and centrifuged at 3,000 rpm at 4 °C for 15 min to remove insoluble mate-
rial. Acidified samples (30 ml/column) were passed through mini columns of Q-Sepharose Fast Flow gel (GE 
Healthcare) (6 ml bed volume × 10 columns per batch of conditioned media) pre-equilibrated with 10 mM 
acetic acid. Unadsorbed peptides were then loaded onto Fractogel CEx weak cation exchange columns (2.8 ml 
bed volume × 10 columns) (Fractogel EMD COO− 650 M; E.Merck) (Fig. 2C). Prior to HPLC eluted fractions 
(Fig. 2C) containing ELDP and CT-proET-1 from Fractogel CEx were desalted by solid phase extraction on C2 
silica cartridges (500 mg, Waters) equilibrated with 0.1% TFA, and eluted with 80% CH3CN containing 0.1% 
TFA. NT-proET-1 was not adsorbed on Q-Sepharose FF gel or Fractogel CEx, and was recovered from the eluate 
passing through both columns by solid phase extraction on C2 silica cartridges.
ProET-1 peptides were subjected to reverse phase HPLC on C4 silica (15 µm, 300 Å pore, 1 × 25 cm; 
Jupiter® Phenomenex) with gradient elution at 2 ml/min: 0.1% TFA – 15% solvent B (80% CH3CN with 0.1% 
TFA) over 2 min, followed by 15–60% B over 45 min. Fractions (1 min) were collected for sandwich immuno-
assay of NT-proET-1, EDLP and CT-proET-1. Peak fractions for each peptide were separately purified using 
higher resolution reverse phase HPLC on C4 silica (5 µm, 300 Å pore, 4.6 × 250 mm; ACE-5 C4–300, Advanced 
Chromatography Technologies) (Fig. 2D,E and F). Synthetic peptides were used to characterise elution positions 
of NT-proET-1, ELDP and CT-proET-1 on this second HPLC system by monitoring absorbance at 280 nm and 
immunoassay of fractions. To avoid contamination by synthetic peptides these peptide standards were only run 
after HPLC of purification of the native peptides.
LC-MS/MS characterisation. The identities of purified ELDP and CT-proET-1 were confirmed by LC-MS/
MS after tryptic digestion (without reduction and alkylation). HPLC fractions containing the highest immu-
noreactivity for ELDP and CT-proET-1 were dried before digesting with sequence-grade trypsin 0.5 µg/µl at a 
final trypsin:protein ratio of 1:50 in 20 mM ammonium bicarbonate buffer, pH 7.8 at 37 °C overnight (18 h). 
Tryptic peptides were separated by nanoflow UPLC using a C18 column (5 µm, 180 µm × 20 mm; Symmetry, 
Waters) eluted with 0.1% formic acid and a gradient of acetonitrile (1–35% over 10 min), and analysed using an 
LTQ-Orbitrap XL MS equipped with a nano-ESI source (positive mode) (Thermo Fisher Scientific). Full scan 
survey spectra (m/z 375–1800) were acquired with a resolution of 30,000 at m/z 400.
Purified NT-proET-1 was analysed in its intact form by nanoACQUITY UPLC using a C4 column (1.7 µm, 
300 Å, 75 µm × 100 mm; BEH300 Waters) by gradient elution at 300 nl/min with 0.1% formic acid and a gradient 
of acetonitrile 5–50% over 25 min and analysed by LTQ-Orbitrap XL MS.
Raw data from MS/MS was subjected to database search using MASCOT (Matrix Science Ltd). In addition, 
theoretical ion fragments from trypsin digestion of ELDP and CT-proET-1 were obtained from ProteinProspector 
(http://prospector.ucsf.edu/) for the endothelin-1 gene EDN1 (P05305, http://www.uniprot.org/uniprot/P05305), 
and raw chromatograms were subsequently analysed using Xcalibur. Fragment ions were identified in the MS/MS 
spectra from Qual Browser and labelled manually for the b- and y-ions, confirming MS/MS fragmentation from 
MASCOT. All samples were run twice on two separate days and only peptides that were present in all analyses are 
described here (see Supplementary Tables S1 and S2, Supplementary Figures S1 and S2).
Evaluation of proET-1 peptides as biomarkers of heart disease. ELDP and CT-proET-1 were meas-
ured using sandwich ELISAs with chemiluminescence detection in plasma samples from patients with stable 
chronic heart failure (HF, n = 24)54, and compared with untreated control subjects with pre-hypertension/mild 
hypertension that were free of any symptoms of ischemic heart disease or heart failure (HYP, n = 24)81. Blood 
samples from patients with stable chronic heart failure were collected at the London Chest Hospital, Barts Health 
NHS Trust, London, UK with the approval of the local research ethics committees and written informed con-
sent of each subject (East London and the City Research Ethics Committee – reference number 07/Q0604/24)54, 
and from untreated subjects with pre-hypertension/mild hypertension were collected in the Centre for Clinical 
Pharmacology, William Harvey Research Institute, Charterhouse Square, London, UK (East London and the 
City Research Ethics Committee – reference number 07/Q0605/44)81. These investigations were performed in 
accordance with the relevant guidelines and regulations. Subject demographic data are summarised in Table 2. 
CRP was measured by ELISA (MP Biomedicals). IL-6, IL-8, MCP-1 and TNFα were measured in samples from 
with patients with chronic heart failure by multiplex assay technology (CVD panel 2 – inflammation, Novagen/
Merck Chemicals) read on a Luminex 200 System.
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Animal studies. All experiments were conducted according to the Animals (Scientific Procedures) Act 1986, 
UK, and approved by the UK Home Office. Clearance rates of proET-1 peptides and blood pressure effects of 
ELDP were determined in male Wistar rats (Charles River) anaesthetised with sodium thiopentone (120 mg/kg 
i.p.). Peptides were administered i.v. via a polyethylene catheter in the left femoral vein. Blood samples (0.5 ml) 
were collected from a catheter in the left carotid artery into chilled 1.5 ml microcentrifuge tubes containing 
50 U/5 µl of heparin. Samples were centrifuged at 12,000 rpm for 2 min at 4 °C. Plasma (50 µl aliquots) samples 
were stored at −80 °C for subsequent analyses. Blood pressure and heart rate were recorded from the left carotid 
artery via a polyethylene catheter using Labchart 7.1 (AD Instruments Ltd).
Vasoconstrictor actions of ELDP and interactions with ET-1 were investigated using rat isolated mesenteric 
resistance arteries mounted in an automated tension myograph (Danish Myo Technology, Denmark) following 
previously described methods82, 83. Contractile responses are expressed as a percentage of the maximal responses 
to phenylephrine (10 µM).
Statistical analyses. Data were analysed using GraphPad Prism 6.0 (GraphPad Software Inc.). Results are 
shown as mean ± SD except for studies of cardiovascular effects which are mean ± SEM. Statistical differences 
were determined by analysis of variance with post hoc Bonferroni multiple comparisons test, or by t-test for 
two group comparisons. Plasma values from patients with chronic heart failure were compared to disease free 
controls using ROC (Receiver Operating Curve) analyses, with difference between areas under the curve (AUC) 
assessed using StAR software84. ROC analyses were adequately powered for a phase 1/exploratory assessment of 
a diagnostic biomarker85.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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